info@upjac.com  | +1 (347) 486-4833

United Conference of B2B

Theme : Novel trends and approaches in Pharmaceutical Industry

Webinar on B2B | July 14-15, 2021

Exhibitors
Sponsorships
Conferences 2022

About The Conference

On behalf of United Conferences, we are overwhelmed to welcome all the interested participants to attend “United Conference of Pharma B2B” Webinar on July 14-15, 2021. This conference boats of a huge variety of Keynote presentations, plenary talks, Poster presentations and Career development programs.

United Conference on Pharma B2B aims to bring together a significant number of leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Research and Development on Pharmaceutical Industry It is a foremost integrative platform for researchers, educators and practitioners alike to present and explore the latest innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in Pharma Industry.

Previous Keynotes

Hashim Ahmed
Hashim Ahmed

WHO Fellow, Sr. Director-Head Of Formulation And Manufacturing, Avomeen, United States

Ravi Kalyanaraman
Ravi Kalyanaraman, Ph.D.

Director, Global Analytical Science & Technology - Pharma & Forensics Bristol Myers Squibb, United States

Timur Güvercinci
Timur Güvercinci

Director, Head of External Supply Quality Processes and Development bei Merck Gruppe Global Quality, Germany

Stephan O. Krause
Stephan O. Krause

Head of Product Quality Group at AstraZeneca Biologics, USA

Gareme Ladds
Graeme Ladds

CEO PharSafer Associates Ltd - Global Leaders in Drug Safety, United Kingdom

Asif Mahmood
Asif Mahmood

Chief Safety Officer/Vice President Global Safety & Pharmacovigilance, Medicago, Canada

Sunil Verma
Sunil Verma

DIRECTOR – PHARMACOVIGLANCE, HAROM Solutions, India

Abdalla Abotaleb - (WHO)

Project Manager, World Health Organization, Spain

Mathew Cherian
Mathew Cherian

Director & Senior Fellow Pharmaceutical Development, Hospira, a Pfizer Company, United States

Eluemuno R Blyden

Founder/CEO at Avril Biopharma, inc., United States

Damon Smith
Damon Smith

CEO TALLC Corporation Inc., Mirabel, Quebec, Canada

Ali Moghaddam
Ali Moghaddam

Vice President & General Manager, Toronto, Ontario, Canada

Jim Hauske

President and founder at Sensor Pharma, United States

Li, Fengzhi
Li, Fengzhi

Faculty member at Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, USA

James T. O'Donnell
James T. O'Donnell

Pharmacologist Drug Expert, Associate Professor at Rush Medical College, United States

Ongoing Keynotes

Mark Nuijten
Mark Nuijten

A2M, member of the MINERVA Health Economics Network, Ltd

brahim Ghareeb Madian Mohammed
Ibrahim Ghareeb Madian Mohammed

GMP executive Consultant

A. C. Matin
A. C. Matin, Ph. D.

Professor of Microbiology & Immunology, Stanford University School of Medicine, USA

Ying-Xian Pan, MD/PhD

Professor Department of Anesthesiology, Rutgers New Jersey Medical School, USA

Shreya Badhrinarayanan, MD

Medical Director | Clinical Development

Dr. Gheorghe FUNDUEANU
Dr. Gheorghe FUNDUEANU

Petru Poni” Institute of Macromolecular Chemistry-Iasi-Romania, Department of Natural Polymers, Bioactive and Biocompatible Materials, Romania.

Vuong Trieu
Vuong Trieu

Chairman & CEO at Oncotelic Therapeutics, USA

Speakers

Dhaval Surti

Heading QA, Emcure Pharmaceuticals Limited, India

Md. Saddam Nawaz

Head of Quality Assurance, ACI HealthCare Limited, Bangladesh

Elie Arslan
Elie Arslan

Manager, Technical QA and Document Control at Ajinomoto Bio-Pharma, United States

Majdi Ayoub

Quality & Validation Manager at Rieckermann GmbH Jordan

Dishant Sanghavi

Senior Manager - Global Quality and Compliance, Sun Pharma, India

Mohammad Refaat Khattab, Ph.D

Scientist at Texas A&M University - USA

Virtual Exhibitors

GCP-Central-Logo_white
GCP Central
ASTE Logo

ASTE Pharmaceuticals, Medical & Laboratory Supplies

TGMP Consulting

Informed DNA
Informed DNA
Diamond Pharmaceuticals

Webinar Registration Charges

  • Keynote/ Speaker Registration 199 USD
  • Speaker Registration 149 USD
  • Delegate Registration 99 USD
  • Student Delegate Registration 50 USD
  • Poster Presentation Registration 50 USD
  • Video Presentation Registration 50 USD
  • E-Banner Registration 50 USD

Who Can Attend

  • Pharma IT & Data
  • Big Data
  • FAIR Data
  • Data Management
  • Data Analytics
  • R&D IT
  • Real-World Data & Evidence
  • AI in Drug Development
  • Machine Learning
  • AI Tools
  • SmartLabs
  • Lab Informatics
  • Automation
  • Robotics
  • Hospitals, healthcare system & healthcare providers
  • Health insurance companies
  • Biotech companies
  • Healthcare-related associations and foundations
  • Molecular Design
  • Modelling Platforms
  • Research IT
  • Chemoinformatics
  • Bioinformatics
  • Machine Learning Tools
  • Custom AI Solutions
  • Research Institutes and members
  • AI Softwares & Platforms
  • Discovery Workflow
  • Lab Compliance
  • Computerized Systems
  • Managers, Directors, and VPs
  • Pharmaceutical companies
  • Medical device manufacturers
  • Industry influencers (solutions providers, educational organizations, government entities and venture capitalists)

Why Choose Us

  • Global & Local Expertise
  • Prospective Attendees
  • Larger worldview of the profession
  • We’re passionate about what we do
  • We focus on your career growth
  • Transparency in Communication
  • Open gateway towards INNOVATION
  • Strong sense of identification
  • Quality without compromise
  • Highly organised and structured scientific programs

Key Takeaways

  • Professional Worldwide
  • International Recognition of Researchers
  • Knowledge into Asset
  • Cognizance of leading Cutting – Edge technologies
  • Publication of Abstracts in preeminent supported journals
  • New Accomplishments with Edu – tech ideas
  • Exposure to the upcoming business trends
  • Free access to our forthcoming International events
  • Certificate of presentation with International signatories

United Pharma Technologies Collaborations and Associations

Penelope Przekop
Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy
Biography: Penelope Przekop, MSQA, RQAP-GCP is the CEO of PDC Pharma Strategy, a consulting firm that focuses on strategic GxP regulatory and corporate compliance. She currently dedicates half of her time to serving as Chief Compliance Officer for Engrail Therapeutics, Inc. She has 30-plus years of broad and deep pharma industry experience and is known for her creative approaches to developing efficient quality management strategies that enable companies of all sizes to build upon their unique drug development history and strengths while ensuring compliance.
Penelope earned her B.S. in Biology from Louisiana State University and her M.S in Quality Systems Engineering from the Kennesaw State University. She is a frequent industry speaker and writer. She is the author of Six Sigma for Business Excellence (McGraw-Hill). Her upcoming book, 5-Star Career (Productivity Press, fall 2021), will relay how readers can apply the proven science of quality management to career development.
Stephan O. Krause
Stephan O. Krause
Head of Product Quality Group at AstraZeneca Biologics, USA
Biography: Stephan Krause, PhD, is currently Quality Director and PQL Team Leader in Development Quality, AstraZeneca Biologics. He is a results-driven leader with 20 years of technical, managerial, and executive experiences for quality and technical functions within global operations. He is a frequent conference presenter and author and has won multiple industry awards for his publications and leadership in improving industry best practices. Stephan was invited by FDA several times to present an industry perspective to the agency on relevant current topics. He is a member of PDA’s Board of Directors and is co-chair of AMTP Advisory Board and a member of the Advisory Board for Biopharmaceuticals and Regulatory Affairs/Quality.
Biography: Graeme Ladds has worked in Global Pharmacovigilance and Medical Affairs for the last 30 years working with many top ten Pharma in senior positions. He has worked in all areas of Pharmacovigilance and has designed and improved many IT solutions to aid both Medical Affairs and Pharmacovigilance. Graeme is also an experienced GCP/PV auditor having audited many Companies globally as well as helping Companies in Regulatory Inspections. He now works in his CRO - PharSafer Associates Ltd
Liana Kasyan
Liana Kasyan
Founder/CEO and Principal PV Consultant at ETL Pharmacovigilance Center Ltd. Armenia
Biography: Founder/CEO and Principal PV Consultant at the ETL Pharmacovigilance Center Ltd., - Pharmacovigilance Instructor at the Open Education Office of the American University of Armenia, - Member of International Society of Pharmacovigilance (ISoP), - International Editorial Board Member for the Journal of Pharmacovigilance and Drug Research (JPADR), - Reviewer of Master Тheses at the Faculty of Public Health of Yerevan State Medical University, - Board Member of Armenian Association of Specialists in Evidence-Based Medicine (AASEBM), - Co-founder of “Do not Harm’’ Health NGO.
Biography: Fengzhi Li became a faculty member at Roswell Park Comprehensive Cancer Center (legal name: Roswell Park Cancer Institute, the first cancer institution in the US history and is a US NCI-designated comprehensive cancer center) in 2001 after finishing his postdoctoral training in Dr. Dario C. Altieri’s laboratory at Boyer Center for Molecular Medicine, Yale Medical School where he focused his research on the characterization of the function and expression regulation of a newly discovered antiapoptotic protein named survivin (a novel member of the inhibitor of apoptosis protein family). In 2006 he has been promoted to Associate Professor of Oncology at Roswell Park. As a chief scientist, he leads his lab using the survivin gene as a target and biomarker for targeted drug discovery. He has transitioned his Roswell Park cancer research lab from basic to translational cancer research over the past decade. His current research interests focus on targeted anticancer drug discovery, development and mechanism of action (MOA) studies. His research has been supported through federal agencies (NIH/NCI, DOD) as well as other public/private foundations and partnerships. He has published over 80 publications (h-index, 47 and i10-index, 73) with a total citation of over 13,000 times. He is the editorial board members in several academic journals including J Exp Clin Can Res (2019 IF: 7.068), Am J Transl Res (2019 IF: 3.375) and Int J Mol Sci (2019 IF: 4.556). He is also the Chief Scientific Officer (CSO) of Canget BioTekpharma LLC (www.canget-biotek.com) and helps Canget to develop innovative targeted anticancer drugs (high efficacy with low toxicity) for benefiting cancer patients.
Mark Nuijten
Mark Nuijten
A2M, member of the MINERVA  Health Economics Network, Ltd, Netherlands
Biography: Mark is medical doctor, health economist, valuation economist, and healthcare journalist. Mark has become a leading health policy and economics expert over the last two decades, reflected in more than 200 publications and leading positions in scientific societies and editorial boards. Mark was Board Director of ISPOR (2002-2004) and Chair of the Management Board of Value in Health (2002-2004). He was member of the Editorial Advisory Board of Value in Health. He obtained his PhD in health economics (2003) on the thesis “In search for more confidence in health economic modelling” at the Erasmus University, Rotterdam.
Mark is founder of A2M (Ars Accessus Medica) and founding partner of the Minerva International Health Economic Network. Mark was trained as a physician and worked in clinical research before obtaining his international M.B.A. from Erasmus University, Rotterdam, where he later was senior staff member. Prior to setting up Ars Accessus Medica, Mark was a partner with MEDTAP International. As a VP Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for MEDTAP. Before his MEDTAP period, Mark was Managing Director of the IQVIA Quintiles office in the Netherlands, which included European responsibility for the policy and health economic division.
brahim Ghareeb Madian Mohammed
Ibrahim Ghareeb Madian Mohammed
GMP executive Consultant
Biography: Quality-oriented pharmaceutical professional with 12 years’ experience in Quality assurance environment. Having sound experience in quality system improvement and in-depth knowledge in diverse GMP guidelines qualified me to be part of a global consultancy entity as GMP executive Consultant"
A. C. Matin
A. C. Matin
Professor of Microbiology & Immunology, Stanford University School of Medicine, USA
Biography: Dr. Matin has been a full professor at Stanford University for several years and is affiliated with several programs, including the Stanford Cancer Research Institute. He has contributed to many areas of biological research, including discovery of new drugs and therapeutic enzymes and their improvement as well as their specific targeting to cancer (and other diseases). He did his Ph. D. at UCLA, spent some years in the Netherlands (State University of Groningen), where he directed a research group, before joining Stanford. He is recipient of numerous awards and honors.
Ying-Xian Pan, MD/PhD
Professor Department of Anesthesiology, Rutgers New Jersey Medical School, USA
Biography: Ying-Xian Pan, MD/PhD is a Professor at the Department of Anesthesiology, Rutgers New Jersey Medical School. Core Member of Brain Health Institute, Rutgers University/Rutgers Biomedical and Health Sciences, USA.
Shreya Badhrinarayanan
Medical Director | Clinical Development
Biography: Dr. Shreya Badhrinarayanan, M.D.,  is an experienced physician with profound clinical and industry experience alongside a passion for improving patient outcomes. She has a proven track-record of providing strategic direction and leading clinical trials through collaboration with cross-functional teams. She has a thorough understanding of ICH GCP guidelines, Adverse Event Reporting, and SOPs while being well-versed in study design and execution, data analysis, and manuscript preparation. She has presented at numerous world-renowned conferences and published in high impact peer-reviewed journals. Thriving in the field of Medical Research, Leadership and Management showcased through her book and media contributions, she was nominated for the Forbes 30 under 30 Europe 2020 Healthcare Awards. During her spare time, she enjoys attending hackathons to turn ideas into reality.
Dr. Gheorghe FUNDUEANU
Dr. Gheorghe FUNDUEANU
Petru Poni” Institute of Macromolecular Chemistry-Iasi-Romania, Department of Natural Polymers, Bioactive and Biocompatible Materials, Romania.
Biography: Dr. Gheorghe FUNDUEANU is a senior researcher, Head of the Department of Natural Polymers, Bioactive and Biocompatible Materials, "Petru Poni" Institute of Macromolecular Chemistry, Romanian Academy, Iassy, Romania.

Expertise Fields: Smart polymeric materials for biomedical applications; drug delivery systems based on polymers; biomimetic hydrogels; cell culture; in vitro and in vivo testing of the polymeric biomaterials; protocols for the determination of the pharmaceuticals in biological fluids and pharmaceutical formulation.
Vuong Trieu
Vuong Trieu
Chairman & CEO at Oncotelic Therapeutics, USA
Biography: Dr. Trieu, an expert in pharmaceutical development, currently serves as CEO/Chairman of Oncotelic Inc.. Previously he was President and CEO of Igdrasol- developer of 2nd generation Abraxane- where he pioneer the regulatory pathway for approval of paclitaxel nanomedicine through a single bioequivalence trial against Abraxane. When Igdrasol merged with Sorrento Therapeutics, he became CSO and Board Director. He was Board Director of Cenomed- a company focusing on CNS drug development.
Before that he was Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis where he lead the development of albumin encapsulated therapeutics along building high throughput platform for small molecules, mirRNA, kinases. Prior to that he was Group Leader at Applied Molecular Evoluton where he was developing biobetter for Humira and Enbrel. Before that he was Director of Cardiovascular Biology at Parker Hughes Institute. Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. He is member of ENDO, ASCO, AACR, and many other professional organization. Dr. Trieu published widely in oncology, cardiovascular, and drug development. Dr. Trieu has over 100 patent applications and 39 issued US patents.

Submit Manuscript

Manuscript Details

Author Details